CG Labz
Peptide Library / Longevity / Cellular

FOXO4-DRI

Senolytic peptide

FOXO4-DRI Research Protocol

Complete Research Guide 4 min read1 peer-reviewed references

Quickstart Overview

FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 inside senescent cells. Breaking this interaction selectively pushes senescent ('zombie') cells into apoptosis — making it a prototype senolytic studied in aging research.

Reconstitution
Add 2.0 mL bacteriostatic water to a 10 mg vial → 5 mg/mL
Literature Range
Intermittent dosing, study-dependent
Measuring Reference
At 5 mg/mL: 1 mg = 0.2 mL = 20 units
Frequency
Intermittent/cyclic
Route (studies)
Subcutaneous
Class
Senolytic peptide

Scientific Data

Molecular Formula
—
Molecular Weight
—
Sequence
D-retro-inverso FOXO4 p53-interacting peptide
Sequence Length
36
CAS
Research compound
Peptide Family
Senolytic peptide
Half-life
Refer to published literature
Solubility
Bacteriostatic water, sterile saline
Storage
Lyophilized: -20°C. Reconstituted: 2–8°C, use within 2–4 weeks.
Appearance
White lyophilized powder
Standard: 10 mg vial · 2 mL diluent

Dosing & Reconstitution Guide

Interactive Reconstitution
Adjust vial size, diluent and target dose. Results update live.
Full Precision Calculator →
Concentration
5.00 mg/mL
Draw Volume
0.200 mL
Syringe Units
20.0 U
Doses / Vial
10

Units assume a U-100 insulin syringe (100 units = 1 mL). A senolytic used intermittently ('hit-and-run'), not continuously.

Frequency: Intermittent/cyclic

Reconstitution Steps

  1. 1Allow the lyophilized vial and bacteriostatic water to reach room temperature (~15 min).
  2. 2Swab both vial stoppers with a fresh 70% isopropyl alcohol pad and let them dry.
  3. 3Draw 2.0 mL of bacteriostatic water into a mixing syringe.
  4. 4Insert at an angle and let the water run slowly down the glass wall — never directly onto the powder.
  5. 5Gently swirl (do not shake) until the solution is completely clear.
  6. 6Label with date and concentration (mg/mL) and refrigerate at 2–8 °C immediately.

Supplies Needed

Planning example for a 4-week protocol at approximately 1000 mcg per day.

Peptide (10 mg vials)
Estimate vials from total mass: 1000 mcg/day × 28 days.
Bacteriostatic Water
One 10–30 mL vial typically covers a full cycle.
Insulin Syringes (U-100)
One per administration (29–31 G, 0.3–0.5 mL).
Alcohol Swabs
Two per administration (vial + site).
Sharps Container
Required for safe disposal.

Protocol Overview

Goal
Model targeted senescent-cell clearance.
Schedule
Intermittent cycles.
Dose Range
Per study design.

Dosing Protocol

Protocol (animal)
Intermittent dosing (e.g. every few days) in cycles
Frequency
Intermittent, cyclic
Target
Per research design
Cycle Length
Short cycles with breaks
Timing
Intermittent 'hit-and-run' dosing
Route
Subcutaneous

Storage Instructions

Lyophilized
−20 °C long term (18–24 months); stable at room temperature for short transit.
Reconstituted
2–8 °C refrigerated; use within 4 weeks.
Light
Protect from direct light; keep in the original carton.
Freeze/Thaw
Avoid repeat freeze–thaw cycles after reconstitution.

Important Notes

  • Highly experimental; human dosing is not established.
  • Used intermittently in cycles rather than continuously.

How This Works

In senescent cells, FOXO4 sequesters p53 in the nucleus, keeping the cells alive but dysfunctional and pro-inflammatory. FOXO4-DRI (a protease-resistant D-amino-acid retro-inverso peptide) competitively blocks the FOXO4-p53 interaction, releasing p53 to trigger apoptosis specifically in senescent cells while sparing healthy ones. In aged mice this restored fitness, fur density and kidney function, demonstrating targeted senescent-cell clearance.

Potential Benefits & Side Effects

Reported in research
  • Selective clearance of senescent cells (senolytic)
  • Restored tissue function in aged mouse models
  • Reduced senescence-associated inflammation
  • Protease-resistant D-retro-inverso design for stability
Possible considerations
  • Experimental — minimal human data
  • Injection-site reactions
  • Theoretical effects on healthy p53 signalling
  • Dosing in humans not established

Lifestyle Factors

  • Adequate hydration and 7–9 h of sleep are standard controls in most research protocols.
  • Consistent dose timing improves the reliability of any self-tracked endpoints.
  • Maintain a clean, sterile workflow for every draw to avoid contamination.

Injection Technique

  1. 1Wash hands, then prep the vial top and the target site with separate alcohol swabs.
  2. 2Pinch a subcutaneous skin fold (abdomen, ~2 inches from the navel) and insert at 45–90°.
  3. 3Depress the plunger slowly over 3–5 seconds, hold 5 seconds, then withdraw.
  4. 4Rotate sites each administration and dispose of the syringe in a sharps container.

Frequently Asked Questions

Third-party HPLC testing

CG Labz Verified Batches

No published batches yet.

Research Disclaimer

All compounds are supplied strictly for laboratory research. Dosing figures below summarize ranges reported in published preclinical and clinical literature for reference purposes only. CG Labz does not provide medical advice or individualized dosing recommendations.

Peer-reviewed literature

References

  1. [1] Cell
    Baar M.P. et al. Targeted apoptosis of senescent cells restores tissue homeostasis (FOXO4-DRI).
    View Source